Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
First Claim
Patent Images
1. A compound of formula (Ia)W-L-Z (Ia) and/or enantiomers, diastereomers or pharmaceutically acceptable salts thereof, wherein:
- W is —
C(=O)R6, —
C(OH)R6(R6), —
C(=O)OR6, —
C(=O)NR6R6, alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, wherein the alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl may be optionally substituted with R1, R1a, R1b, R1c and R1d;
R1, R1a, R1b, R1c and R1d are independently hydrogen, halogen, —
OH, —
CN, −
NO2, —
CO2R6, —
CONR6R6, —
SO2NR6R6, —
SOR6, —
SO2R6, —
NR6SO2R6, —
NR6CO2R6, —
OCONR6R6, tetrazolyl, alkyl, haloalkyl, cycloalkyl, alkoxy, aryloxy, alkenyl, haloalkoxy, alkylthio, arylthio, arylsulfonyl, alkylamino, aminoalkyl, arylamino, heteroarylamino, aryl, heteroaryl or heterocyclyl, wherein the tetrazolyl, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl may be optionally substituted with R7, R7a, R7b, and R7c;
or alternatively any two R1, R1a, R1b, R1c and R1d can be taken together to form a fused cycloalkyl, aryl, heteroaryl, heterocyclyl ring or spiro heterocyclyl ring;
L is a bond, 0, SO, SO2, C(=O), alkenyl, cycloalkyl, CR2R2a, CR2R6, CR2R2aCR2bR2c, SO2NR6, OCR2R2a, OCR2R2aCR2bR2c, CR2R2aO, CR2bR2cCR2R2aO, N(R5)CR2R2a, CR2R2aSO, CR2R2aSO2, SOCR2R2a, SO2CR2R2, CR2R2aOCR2bR2c, CR2R2aSCR2bR2c, CR2R2aSO2CR2bR2c, SO2NR6CR2aR2b, COCR2R2a , CR2R2aCO, CONR6CR2aR2b, CR2R2aCR2bR2cS, CR2R2aCR2bR2cSO, CR2R2aCR2bR2cSO2;
R2, R2a, R2b and R2c are independently hydrogen, halogen, —
OH, alkyl, cycloalkyl, aryl, or haloalkyl;
or alternatively any two R2, R2a, R2b, and R2c can be taken together to which the atom they are attached to form a cycloalkyl, halogen substituted cycloalkyl or heterocyclyl ring;
Z is;
1 Assignment
0 Petitions
Accused Products
Abstract
Novel compounds are provided which are 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors. 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 1 1-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: W-L-Z or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L are defined herein and Z is selected from the following bicyclic heteroaryl groups: (a), (b), (c), (d).
36 Citations
19 Claims
-
1. A compound of formula (Ia)
W-L-Z (Ia) and/or enantiomers, diastereomers or pharmaceutically acceptable salts thereof, wherein: -
W is —
C(=O)R6, —
C(OH)R6(R6), —
C(=O)OR6, —
C(=O)NR6R6, alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, wherein the alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl may be optionally substituted with R1, R1a, R1b, R1c and R1d;R1, R1a, R1b, R1c and R1d are independently hydrogen, halogen, —
OH, —
CN, −
NO2, —
CO2R6, —
CONR6R6, —
SO2NR6R6, —
SOR6, —
SO2R6, —
NR6SO2R6, —
NR6CO2R6, —
OCONR6R6, tetrazolyl, alkyl, haloalkyl, cycloalkyl, alkoxy, aryloxy, alkenyl, haloalkoxy, alkylthio, arylthio, arylsulfonyl, alkylamino, aminoalkyl, arylamino, heteroarylamino, aryl, heteroaryl or heterocyclyl, wherein the tetrazolyl, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl may be optionally substituted with R7, R7a, R7b, and R7c;or alternatively any two R1, R1a, R1b, R1c and R1d can be taken together to form a fused cycloalkyl, aryl, heteroaryl, heterocyclyl ring or spiro heterocyclyl ring; L is a bond, 0, SO, SO2, C(=O), alkenyl, cycloalkyl, CR2R2a, CR2R6, CR2R2aCR2bR2c, SO2NR6, OCR2R2a, OCR2R2aCR2bR2c, CR2R2aO, CR2bR2cCR2R2aO, N(R5)CR2R2a, CR2R2aSO, CR2R2aSO2, SOCR2R2a, SO2CR2R2, CR2R2aOCR2bR2c, CR2R2aSCR2bR2c, CR2R2aSO2CR2bR2c, SO2NR6CR2aR2b, COCR2R2a , CR2R2aCO, CONR6CR2aR2b, CR2R2aCR2bR2cS, CR2R2aCR2bR2cSO, CR2R2aCR2bR2cSO2; R2, R2a, R2b and R2c are independently hydrogen, halogen, —
OH, alkyl, cycloalkyl, aryl, or haloalkyl;or alternatively any two R2, R2a, R2b, and R2c can be taken together to which the atom they are attached to form a cycloalkyl, halogen substituted cycloalkyl or heterocyclyl ring;
Z is; - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
-
15. A compound of formula (Ib)
W-L-Z (Ib) and/or enantiomers, diastereomers or pharmaceutically acceptable salts thereof, wherein: -
W is —
C(=O)R6, —
C(OH)R6(R6), —
C(=O)OR6, —
C(=O)NR6R6, alkyl, alkenyl, aryl, or cycloalkyl, heteroaryl or heterocyclyl, wherein the alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl may be optionally substituted with R1, R1a, R1b, R1c and R1d;R1, R1a, R1b, R1c and R1d are independently hydrogen, halogen, —
OH, —
CN, —
NO2, —
CO2R6, —
CONR6R6, —
SO2NR6R6, —
SOR6, —
SO2R6, —
NR6SO2R6, —
NR6CO2R6, —
OCONR6R6, tetrazolyl, alkyl, haloalkyl, cycloalkyl, alkoxy, aryloxy, alkenyl, haloalkoxy, alkylthio, arylthio, arylsulfonyl, alkylamino, aminoalkyl, arylamino, heteroarylamino, aryl, heteroaryl or heterocyclyl, wherein the tetrazolyl, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl may be optionally substituted with R7,R7a, R7b, and R7c; or alternatively any two R1, R1a, R1b, R1c and R1d can be taken together to form a fused cycloalkyl, aryl, heteroaryl, heterocyclyl ring or spiro heterocyclyl ring; L is a bond or O; - View Dependent Claims (16, 17)
-
-
18. A compound of formula (I)
W-L-Z-
(I)and/or enantiomers, diastereomers or pharmaceutically acceptable salts thereof, wherein; W is alkyl, alkenyl, aryl, or cycloalkyl, wherein the alkyl, alkenyl, aryl, or cycloalkyl may be optionally substituted with R1, R1a, R1b, R1c and R1d; R1, R1a, R1b, R1c and R1d are independently hydrogen, halogen, —
OH, —
CN, —
NO2, —
CO2R6, —
CONR6R6, —
SO2NR6R6, —
SOR6, —
SO2R6, —
NR6SO2R6, —
NR6CO2R6, —
OCONR6R6, tetrazolyl, alkyl, haloalkyl, cycloalkyl, alkoxy, aryloxy, alkenyl, haloalkoxy, alkylthio, arylthio, arylsulfonyl, alkylamino, aminoalkyl, arylamino, heteroarylamino, aryl, heteroaryl or heterocyclyl, wherein the tetrazolyl, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl may be optionally substituted with R7, R7a, R7b, and R7c;or alternatively any two R1, R1a, R1b, R1c and R1d can be taken together to form a fused cycloalkyl, aryl, heteroaryl, heterocyclyl ring or spiro heterocyclyl ring; L is O; Z is - View Dependent Claims (19)
-
Specification